drugset / Trial / NCT02632474

ART Drug Dosage Adjustment in HIV-infected Population

NCT02632474

Phase 4 Completed 10 enrolled Shanghai Public Health Clinical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine efficacy of the combination of low dose of Tenofovir, Efavirenz and Lamivudine in treating HIV-infection.

Timeline

Start
2015-04
Primary completion
2016-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified 400 mg
Subject Efavirenz Other / unclassified 600 mg
Subject Lamivudine Other / unclassified 300 mg
Subject Tenofovir Small molecule 200 mg
Subject Tenofovir Small molecule 300 mg